(Q40806860)

23 September 2017

title

Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. (English)

1 reference

sexually transmitted infection

23 September 2017

0 references

0 references

author name string

D W Kowalczyk

1

1 reference

23 September 2017

A P Wlazlo

2

1 reference

23 September 2017

S Shane

3

1 reference

23 September 2017

H C Ertl

4

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

23 September 2017

1 reference

23 September 2017

volume

19

1 reference

23 September 2017

issue

25-26

1 reference

23 September 2017

page(s)

3583-3590

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

High throughput method for creating and screening recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

Protection against papillomavirus with a polynucleotide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900070-6

7 January 2021

10.1016/S0264-410X(01)00070-6

Identifiers

DOI

1 reference

23 September 2017

1 reference